Clinical Trial Update: Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating an HLA-A*2402-restricted tumor vessel–specific peptide vaccine for advanced pancreatic cancer, sponsored by the Univers…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• HLA-A*2402-restricted tumor vessel-specific peptide vaccine

Snippet

Sponsor: Tokyo University | Conditions: Pancreatic Cancer, Pancreas Neoplasms | Phase 1, Phase 2 | Status: UNKNOWN